The following clinical trials are being conducted:
SWOG S1007/RxPONDER: – A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less.
SWOG S1400 – MASTER Lung study Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
(Chemotherapy being used in each arm is Docetaxel)
BAYER study: BAY 73-4506 / IMPACT no. 17347:
Does physician education influence side effect management and does it increase time on treatment in the absence of progression? A phase 4 open-label trial with regorafenib in metastatic colorectal cancer.
Also known as the SMART study: Stivarga Management Amelioration Resorting to Technology – physician use an iPad to help manage patient’s side effects.
Oral Anti-Cancer Therapy Research Study - The objective of this study is to assess whether or not patients taking oral anti-cancer therapies (oral antineoplasitc agents) i.e. chemotherapy, targeted biologic therapy, hormone therapy, etc. are adhering to their treatment regimen. If there appears to be a growing trend showing that patients are not adhering to their medication regimen, methods to improve adherence will be studied and implemented
NRG-BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer